The ICE1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HeLa cervical carcinoma line, engineered to carry a targeted disruption of the ICE1 gene. This polyclonal knockout model enables loss-of-function studies of ICE1 in the context of transcription elongation and snRNA gene regulation. The heterogeneous population retains the genetic diversity typical of polyclonal editing, providing a robust system for investigating gene function without clonal selection artifacts.
The HeLa cell line, originally derived from a cervical adenocarcinoma and positive for human papillomavirus type 18 (HPV18), is a well-established epithelial model for cancer biology and gene expression studies. Its rapid proliferation, ease of genetic manipulation, and extensive characterization make it an ideal host for investigating transcription-related pathways. This polyclonal knockout derivative maintains the parental line’s core characteristics while allowing dissection of ICE1-dependent functions in a cancer-relevant background.
ICE1 serves as a scaffold in the little elongation complex (LEC), binding ELL, EAF1, and EAF2 to enable RNA polymerase II (RNA Pol II) elongation at small nuclear RNA (snRNA) genes such as U1 and U2. The LEC is recruited by the Mediator complex and general transcription factors, and its activity is modulated by MAPK and PI3K signaling. CRISPR/Cas9-mediated ICE1 disruption destabilizes the LEC, reducing RNA Pol II processivity at snRNA loci and thereby decreasing snRNA synthesis, which in turn impairs pre-mRNA splicing and alters global transcription.
In the HeLa cervical carcinoma background, loss of ICE1 provides a valuable model for investigating the dependency of cancer cells on efficient snRNA biogenesis and transcription elongation. Given the high metabolic and transcriptional demands of rapidly dividing tumor cells, perturbations in the LEC function may reveal specific vulnerabilities linked to transcription deregulation. This polyclonal knockout system enables researchers to assess the impact of ICE1 loss on cell proliferation, viability, and stress responses within a cancer-derived epithelium, potentially highlighting points of therapeutic intervention in malignancies where transcriptional control is altered.
These polyclonal ICE1 knockout cells support mechanistic studies of transcription elongation, with ChIP-qPCR to monitor RNA Pol II occupancy at snRNA genes, RNA sequencing for transcriptome profiling, and Western blotting or RT-qPCR to verify ICE1 ablation. Cell viability, clonogenic, and immunofluorescence assays enable phenotypic screening for LEC modulators or compensatory factors. The model thus aids the dissection of elongation?Ccancer crosstalk and discovery of molecules targeting transcriptional addiction. For additional information or quotes, contact Ascent Research.
